Membranous nephropathy
Conditions
Interventions
Controlled group:Medications such as irbesartan, valsartan, losartan, telmisartan, candesartan, benazepril, enalapril, or ramipril are given.
Experiment group:Medications such as irbesartan, valsartan, losartan, telmisartan, candesartan, benazepril, enalapril or ramipril and ambrisentan are given.
Sponsors
The Second Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with idiopathic membranous nephropathy: patients with pathological diagnosis of membranous nephropathy by renal biopsy and pathological immunofluorescence PLA2R(+), or positive serum anti-PLA2R antibody, or pathological histologic immunofluorescence IgG4 positive and judged to be idiopathic membranous nephropathy; (1) Albumin > 30g/L and urine protein-to-creatinine ratio (UPCR) still >= 0.75 g/g (2 consecutive assays) after supportive care, hormonal and/or immunosuppressive agents and/or biologics; (2) Hormones or immunosuppressants have been discontinued for at least 1 month, or biologics treatment is judged to have been terminated for at least 1 month. 2. Patient is able to understand the study procedures and comply with them throughout the study period; 3. Age 18-80 years old; 4. Measure eGFR >=45ml/min/1.73m^2 (calculated by the Chronic Kidney Disease Epidemiology Cooperative Study Formula (CKD-EPI)) during the screening period (within 30 days after signing the informed consent).
Exclusion criteria
Exclusion criteria: 1.Chronic kidney failure: Abnormal kidney structure or function or kidney transplantation = 3 months, imaging or laboratory examination shows hematuria, proteinuria, kidney abnormalities; or glomerular filtration rate (GFR) 3.0 times the upper limit of normal (ULN), history of hepatic encephalopathy, esophageal varices, portacaval shunt surgery, or Child-Pugh Class C liver cirrhosis; 6) Evidence of urinary tract obstruction or difficulty voiding; 12.A history of other malignant tumors in the past 5 years; 13.A history of organ transplantation or chronic liver disease; 14.Life expectancy of less than one year; 15.Currently dependent on drugs or alcohol; 16.People who have lost their capacity for independent action; 17.The researchers believed that it was not appropriate to participate in clinical research; 18.The individual or his/her legal guardian/representative is unable or unwilling to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoint;Adverse events; | — |
Countries
China
Contacts
Public ContactZhao jinghong
The Second Affiliated Hospital of Army Medical University
Outcome results
None listed